Clearmind Medicine Inc. Advances Its Alcohol Use Disorder Trial, Driving a Stock Surge
On November 13, 2025, Clearmind Medicine Inc. (NASDAQ: CMND) experienced a sharp rally on the Nasdaq after announcing a pivotal development in its clinical program for alcohol use disorder (AUD). The company disclosed that the Hadassah Medical Center in Jerusalem had granted final approval to join its ongoing Phase 1/2a clinical trial of CMND‑100, a proprietary methoxy‑2‑aminoindane (MEAI)‑based oral therapy. This approval not only expands the geographic footprint of the study but also signals confidence from a respected Israeli medical institution in Clearmind’s investigational product.
What the Announcement Means for the Trial
The Phase 1/2a study, which has already completed its first cohort of patients, now benefits from an additional enrollment site at Hadassah. The trial roster already includes high‑profile U.S. and Israeli centers such as the Yale School of Medicine Department of Psychiatry, Johns Hopkins University School of Medicine, and Tel Aviv Sourasky Medical Center. By adding Hadassah, the company is expected to accelerate recruitment, diversify its patient population, and enhance the robustness of its efficacy and safety data.
CMND‑100 is a non‑hallucinogenic MEAI compound, distinct from many psychedelic‑derived therapeutics that rely on serotonergic activity. Preclinical work has highlighted MEAI’s ability to modulate mood and reward pathways, which could translate into a novel mechanism for reducing alcohol craving and relapse. Clearmind’s focus on neuroplasticity‑based therapies positions it at the forefront of a rapidly growing segment of psychiatric treatment research.
Market Reaction
The announcement triggered a notable increase in share price. As of the close on November 11, 2025, CMND traded at $0.31, a modest figure relative to its 52‑week high of $2.18 on December 23, 2024. The 2025‑year low of $0.24 reflects the company’s typical volatility, a common characteristic among early‑stage biotech firms. The price‑earnings ratio of –1.2 underscores that the company is not yet profitable, yet the market appears to be rewarding the perceived upside from the clinical milestone.
The surge on November 13 suggests that investors are placing greater confidence in the company’s ability to translate its MEAI platform into a marketable product. The inclusion of a reputable Israeli clinical site may also mitigate perceived regulatory and logistical risks associated with global trials.
Broader Context: Depression Pipeline
In addition to the AUD news, Clearmind disclosed a notice of publication by the China National Intellectual Property Administration regarding a patent for a MEAI‑based compound intended for depression treatment. While the company’s primary focus remains on AUD, this patent filing signals an expansion of its therapeutic pipeline. Major depressive disorder affects more than 280 million people worldwide, and the availability of a non‑hallucinogenic, neuroplasticity‑based therapy could fill a substantial unmet need.
Outlook
Clearmind Medicine Inc. remains a clinical‑stage company with a market capitalization of approximately $2.5 million. Its operations are headquartered in Canada and it trades on the Nasdaq, reflecting its ambition to bring innovative therapies to a global market. The recent approval by Hadassah Medical Center marks a critical step toward broader patient recruitment and enhanced data quality for CMND‑100. As the company progresses through subsequent phases of its AUD program and potentially advances its depression pipeline, the market will likely continue to monitor its milestones closely.
